ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1507

Role of CD4+ T Cells in the Pathogenesis of RA: Immunization with Citrullinated T Cell Epitopes Is Sufficient to Induce Immunological and Clinical Manifestations of Arthritis in DR4-Transgenic Mice

Elena Tonti1, Bhargavi Duvvuri2, Sudeshna Dhar1, Derek Haaland3, Maggie Larche1 and Mark Larché1, 1McMaster University, Hamilton, ON, Canada, 2University of Washington, Seattle, WA, 3McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada

Meeting: ACR Convergence 2021

Keywords: Animal Model, citrullination, immunology, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (1507–1515)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Although the etiology of rheumatoid arthritis (RA) remains unclear, existing research suggests a complex interplay of both genetic and environmental factors. Citrullinated proteins/peptides, and immune responses to them, may lead to the breaching of immunological tolerance, and subsequent disease. While most research to date has focused on the specificity of anti-citrullinated protein antibodies (ACPAs) in RA, the role of T cell responses to citrullinated peptides remains to be further investigated. The aim of this study is to better understand the involvement of T cells in the pathogenesis of the disease, with the ultimate vision of developing therapeutic interventions for RA.

Methods: HLA-DRA/DRB1*0401 transgenic mice were immunized with two subcutaneous injections of 10 citrullinated T-cell epitopes known to bind to DRB1*0401 and derived from proteins implicated in the development of RA. After 1 week, a second boost was performed, either with citrullinated human fibrinogen protein or with an additional dose of the 10 peptides. Two months after, the mice received an intra-articular (IA) boost in the right knee with a mixture containing 5 citrullinated peptides. All immunizations were performed in complete (for the priming injection, CFA) or incomplete (for the subsequent boosts, IFA) Freund’s adjuvant.

Results: Within weeks of the initial subcutaneous immunizations, the mice developed T-cell responses that were specific for the citrullinated peptides and not for their native counterparts. Remarkably, the injection of citrullinated T cell epitopes was sufficient to induce the production of ACPA, detectable in the blood by ELISA. In addition, the IA boost led to the manifestation of clinical signs of arthritis: mice injected intra-articularly with citrullinated peptides and IFA showed prolonged articular swelling and systemic inflammation in comparison to the control groups. Such signs were even more pronounced in mice previously treated with the citrullinated human fibrinogen protein.

Conclusion: This study shows that immunization with shared epitope-binding citrullinated peptides is sufficient to induce immunological and clinical signs of RA, by triggering arthritogenic T cell responses. These results provide direct evidence of the pathogenic contribution of particular peptides to arthritis and of the pivotal role of T cells in the pathogenesis of the disease. Furthermore, these findings also introduce the possibility of using peptide immunotherapy to re-establish immunological tolerance to RA autoantigens.


Disclosures: E. Tonti, None; B. Duvvuri, None; S. Dhar, None; D. Haaland, AbbVie, 2, 5, 6, Adiga Life Sciences, 5, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Can-Fite BioPharma, 5, Celgene, 5, Eli Lilly, 5, 6, Gilead, 5, GlaxoSmithKline, 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Regeneron, 5, Sanofi, 2, 5, 6, UCB, 2, 5, 6, AstraZeneca, 6, Merck, 6, Takeda, 2, 6, Roche, 2, 6; M. Larche, Adiga Life Science Inc, 10; M. Larché, Adiga Life Sciences Inc, 2, 5, 10, Vaxerna Ltd., 2, 8, Circassia Pharmaceuticals PLC, 8.

To cite this abstract in AMA style:

Tonti E, Duvvuri B, Dhar S, Haaland D, Larche M, Larché M. Role of CD4+ T Cells in the Pathogenesis of RA: Immunization with Citrullinated T Cell Epitopes Is Sufficient to Induce Immunological and Clinical Manifestations of Arthritis in DR4-Transgenic Mice [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/role-of-cd4-t-cells-in-the-pathogenesis-of-ra-immunization-with-citrullinated-t-cell-epitopes-is-sufficient-to-induce-immunological-and-clinical-manifestations-of-arthritis-in-dr4-transgenic-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-cd4-t-cells-in-the-pathogenesis-of-ra-immunization-with-citrullinated-t-cell-epitopes-is-sufficient-to-induce-immunological-and-clinical-manifestations-of-arthritis-in-dr4-transgenic-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology